Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) has issued an update.
Q-linea AB has announced the initiation of two new clinical evaluations of its ASTar system in Saudi Arabia and Kuwait, in collaboration with AMICO Group. These evaluations aim to integrate ASTar into routine clinical use in the GCC region, enhancing patient outcomes and productivity in hospitals already familiar with rapid AST practices.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea is a Swedish company specializing in rapid antimicrobial susceptibility testing systems, specifically their ASTar® system, which aids in the treatment of bloodstream infections and sepsis by reducing the time to optimal antimicrobial therapies. The company is headquartered in Uppsala, Sweden, with regional offices in Italy and the USA, and has global partnerships.
Average Trading Volume: 19,983
Technical Sentiment Signal: Sell
Current Market Cap: SEK304.4M
Learn more about QLINEA stock on TipRanks’ Stock Analysis page.